Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran Inc is a clinical-stage biopharmaceutical company developing oxygen transport and antiviral therapeutics using proprietary carbohydrate-based technologies. The company's research focuses on two primary platforms: hemoglobin-based oxygen carriers for treating tissue hypoxia, and broad-spectrum antiviral drugs that target galectin proteins involved in viral infection and inflammation.
The oxygen transport platform utilizes hemoglobin stabilized with glyco-polymer technology to create molecules significantly smaller than red blood cells, enabling penetration into ischemic tissues beyond blood clots. Target applications include ischemic stroke, traumatic brain injury, chronic kidney disease, and other conditions where oxygen delivery is compromised. The company has established partnerships to develop Universal Oxygen Carriers as potential alternatives to traditional blood transfusions, addressing global blood supply challenges.
The antiviral program employs glycovirology principles to develop therapeutics that antagonize galectins, preventing viral adhesion to host cells. The lead antiviral candidate uses complex carbohydrate structures to target conserved regions on viral spike proteins, providing potential activity against multiple respiratory viruses. Clinical development has progressed under FDA Investigational New Drug applications, with trials evaluating viral clearance rates and safety profiles.
Bioxytran's research approach combines artificial intelligence analysis of biological targets with rational drug design to create optimized carbohydrate-based molecules. The company maintains patent protection for its co-polymer technologies and continues to advance multiple drug candidates through preclinical and clinical development stages. Strategic collaborations with government agencies and industry partners support the company's development programs and manufacturing capabilities.
News and developments related to Bioxytran typically involve clinical trial progress, regulatory clearances, partnership announcements, financing activities, and research findings related to the company's oxygen transport and antiviral platforms. Investors and stakeholders monitor updates on drug candidate advancement, intellectual property developments, and strategic initiatives that may impact the company's path toward potential product commercialization.
Bioxytran (OTCQB:BIXT) announced on Nov 13, 2025 that Independent Research initiated coverage of the stock and published a report highlighting clinical and corporate updates.
Key clinical data for lead candidate ProLectin-M: 88% viral clearance by day 3 and 100% by day 7 in mild-to-moderate COVID-19, with no serious adverse events reported. The drug targets the galectin fold and is positioned as a potential broad-spectrum antiviral.
Pipeline focus includes ambulatory stroke candidate BXT-25 aimed at expanding the 3-hour treatment window. The report flags funding as the primary risk and notes >50% insider ownership and active pursuit of strategic partnerships.
Bioxytran (OTCQB: BIXT) announced on October 29, 2025 the completion of a randomized, double-blind, placebo-controlled dose-optimization trial for its oral broad-spectrum antiviral candidate ProLectin-M. The company says prior Phase 2 results showed treated participants reached undetectable PCR viral levels in less than one week. Data from the new trial will be used to inform a phase 3 trial design for CDSCO and will be submitted to the FDA at the agency's request. Bioxytran expects to compile detailed safety and efficacy endpoints for peer-reviewed publication and plans to submit full results in the coming weeks.
Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.
The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.
Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.
ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.
The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.
Bioxytran (OTCQB: BIXT) commemorates 50 years of mitochondrial research advancement, highlighting the historical significance of fiber optic-based fluorometry in brain mitochondrial research through a landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University.
The company's lead drug candidate BXT-25 is advancing toward Phase 1 trials, targeting conditions requiring oxygen transport carrier capabilities, including:
- Ischemic stroke
- Heart attack
- Pulmonary embolism
- Chronic kidney disease (CKD)
- Long Covid
The research emphasizes real-time mitochondrial monitoring through the MDX Viewer, an FDA-approved device measuring tissue metabolic score. The company is exploring partnerships to integrate next-generation monitoring technologies for patient selection and vital sign measurements.
Bioxytran (OTCQB: BIXT) has signed a Non-Disclosure Agreement with the University of Georgia to evaluate its galectin antagonists as a potential treatment for bird flu in chickens. The research collaboration will be led by Dr. Daniel Perez, an expert in virology and poultry medicine who serves as CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine at the university.
The company's leading drug candidate, ProLectin-M, is a galectin antagonist designed to fight viral infections by targeting galectins - proteins involved in viral replication, inflammation, and fibrosis. The drug has shown promise in in vitro studies against viruses similar to the bird flu virus, suggesting potential applications in poultry treatment.
FAQ
What is the current stock price of Bioxytran (BIXT)?
What is the market cap of Bioxytran (BIXT)?
